NCT03689010View on ClinicalTrials.gov

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

PHASE1CompletedINTERVENTIONAL
Enrollment

1,116

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

August 9, 2018

Study Completion Date

September 28, 2018

Conditions
Rosacea
Interventions
DRUG

Azelaic acid foam 15%

Azelaic acid foam 15%

DRUG

Finacea® (Azelaic acid Foam) 15%

Azelaic acid foam 15%

DRUG

Vehicle of the test product

Vehicle of the test product

Trial Locations (1)

28217

Catawba Research, LLC, Charlotte

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT03689010 - To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea | Biotech Hunter | Biotech Hunter